Last reviewed · How we verify
Contraceptive implant
At a glance
| Generic name | Contraceptive implant |
|---|---|
| Also known as | Implanon, Nexplanon, etonogestrel contraceptive implant |
| Sponsor | University of North Carolina, Chapel Hill |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception (PHASE2)
- A Comparative Study Evaluating Pain Experienced During Intrauterine Device Insertion in Women
- A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) (PHASE3)
- Long Term Evaluation of Scapular-inserted Contraceptive Implants (PHASE2)
- Exploring the Modulatory Role of Sex Hormones Along the Neuromechanical Axis in Females
- A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom (NA)
- Patient-centered Information on Permanent Contraception (NA)
- Subdermal Implant-bioabsorbable Gestrinone Pellet for Endometriosis Pelvic Pain Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Contraceptive implant CI brief — competitive landscape report
- Contraceptive implant updates RSS · CI watch RSS
- University of North Carolina, Chapel Hill portfolio CI